Population Pharmacokinetics of Adalimumab in Juvenile Idiopathic Arthritis Patients: A Retrospective Cohort Study Using Clinical Care Data.
Amara Nassar-Sheikh RashidFemke HooijbergSandy C BergkampMariken P GruppenTaco W KuijpersMike NurmohamedTheo RispensGertjan WolbinkJ Merlijn van den BergDieneke Schonenberg-MeinemaRon A A MathôtPublished in: Paediatric drugs (2024)
Five literature models effectively described adalimumab PK in this pediatric cohort, highlighting the potential for extrapolating existing models to the pediatric population. The new JIA model confirmed the effect of several known covariates and found a novel association for drug clearance with methotrexate use (lower) and uveitis (higher), which might have clinical relevance for personalized dosing in JIA.
Keyphrases
- juvenile idiopathic arthritis
- disease activity
- end stage renal disease
- ejection fraction
- healthcare
- newly diagnosed
- systematic review
- chronic kidney disease
- rheumatoid arthritis
- palliative care
- peritoneal dialysis
- prognostic factors
- high dose
- patient reported outcomes
- emergency department
- low dose
- young adults
- risk assessment
- ankylosing spondylitis
- pain management
- chronic pain
- ulcerative colitis